A dose escalation study of ORG 10172 (low molecular weight heparinoid) in stroke

Journal Article

An intravenous infusion of a low molecular weight heparinoid, with a reduced risk of hemorrhage, may be an alternative to heparin in the management of acute ischemic stroke. To evaluate this hypothesis, we studied the safety of the heparinoid, ORG 10172, in a dose-escalation study in 26 patients. The drug was administered as a loading bolus followed by a 7-day infusion in five rates with target anti-factor Xa levels from 0.2 to 1.0 U/ml. The drug was well tolerated; no major bleeding complications or thrombocytopenia occurred. There were no deaths or hemorrhagic transformation of cerebral infarctions. The results indicate that ORG 10172 at doses to achieve a level of 1.0 U/ml or less may be used safely in management of acute cerebral infarction.

Duke Authors

Cited Authors

  • Biller, J; Massey, EW; Marler, JR; Jr, HPA; Davis, JN; Bruno, A; Henriksen, RA; Linhardt, RJ; Goldstein, LB; Alberts, M; Kisker, CT; Toffol, GJ; Greenberg, CS; Banwart, KJ; Bertels, C; Beck, DW; Walker, M; Magnani, HN

Published Date

  • 1989

Published In

  • Neurology

Volume / Issue

  • 39 / 2 I

Start / End Page

  • 262 - 265